Rachel McMinn bought $969K of Neurogene (NGNE)
Executed Nov 22 2024, disclosed Nov 25 2024, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 25 2024), the stock returned +7.5% (delay-adjusted); from the execution session (Nov 22 2024), +45.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Rachel McMinn (Chief Executive Officer) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Neurogene Inc. (NGNE). Across 1 priced purchase filing, the average 21-session return was +45.3% from execution and +7.5% from disclosure (delay-adjusted; derived). The largest single filing was $969K of NGNE (47,500 sh × $20.40, as filed), executed Nov 22 2024.
Healthcare · Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→